recovery. Unfortunately, the endogenous regenerative response is limited and does not lead to full recovery after stroke. 7, 8 Mesenchymal stem cells (MSCs) have emerged as powerful strategies to improve stroke recovery. 9 Studies have reported that MSCs harvested from bone marrow (BMSCs) and adipose tissue (Ad-MSCs) could enhance functional recovery and neurogenesis in stroke model. 10, 11 Increasing evidence indicates that stem cells exert therapeutic effects primarily through paracrine actions. 12 Exosomes are critical mediators of cell paracrine action. M. Chopp et al have previously demonstrated that MSC-generated exosomes could enhance the stroke recovery process by promoting neurogenesis. [13] [14] [15] However, the most commonly investigated MSCs, such as BMSCs and Ad-MSCs, have a limited source and require invasive procedures to isolate, severely hampering their clinical applications. Our group isolated a stem cell population from voided urine, which can be conveniently obtained through a simple, non-invasive and low-cost approach. 16, 17 Aside from their capacity for osteogenic, chondrogenic and adipogenic differentiation potential, we further found that urine-derived stem cells (USCs) could also differentiate into neural lineage cells. After transplantation into rat brains, USCs could survive, migrate and differentiate into neuronal lineages at the lesion site. 18 These characteristics make USCs a promising alternative to current MSCs in ischaemic stroke therapy. Nevertheless, few studies have directly utilized exosomes derived from human urine-derived stem cells (USC-Exos) for ischaemic stroke therapy. In the present study, we investigated whether USC-Exos could promote neurogenesis and functional recovery in ischaemic stroke.
Endogenous neurogenesis involves a complex process beginning with the proliferation of NSCs, followed by the differentiation of NSCs into new neurons. 19, 20 Epigenetic modification has emerged as a critical mechanism regulating gene expression in a temporal and spatial manner during proliferation and differentiation of NSCs. 21, 22 Lysine acetylation of histones, which is one of the best characterized epigenetic modifications, is determined by the interplay between 2 classes of antagonistic enzymes, histone acetyltransferases (HATs) and histone deacetylases (HDACs). 23 Recent observations point to a critical role for HDACs in the modulation of NSCs' self-renewal and differentiation by controlling the activity of a network of downstream target genes. 24, 25 Furthermore, pharmacological manipulation of HDAC activities using HDAC inhibitors (HDACis) such as valproic acid (VPA), 24, 26 trichostatin A (TSA), 27 suberoylanilide hydroxamic acid (SAHA) 28 and sodium butyrate 26, 29 promotes differentiation of NSCs into neural cells. HDAC6 is a member of HDAC family. The domain structure of HDAC6 is distinct from that of all other HDACs, as it harbours 2 deacetylase domains and a C-terminal zinc finger domain. 30 Previous research has demonstrated that experimental ischaemic stroke causes an induction of HDAC6 both in vivo and in vitro. 31 Inhibition of HDAC6 significantly promoted neurogenesis and alleviated functional deficits following ischaemic injury. 32, 33 Knock-down of HDAC6 or suppression of HDAC6 level in neurons decreased neurite outgrowth and slowed axonal growth. 34, 35 More importantly, HDAC6 inhibition could promote differentiation of NSCs. 36 Given these observations, HDAC6 represents an interesting regulator in the process of neurogenesis after stroke.
In this study, we investigated the effects of USC-Exos on neurogenesis in ischaemic stroke models, as well as the relationship between HDAC6 expression and USC-Exos-induced neurogenesis. Our in vivo study indicated that USC-Exos could promote endogenous neurogenesis and enhance the repair of neurological functions in post-ischaemic stroke rats. We further found that USC-Exos increased both proliferation and neuronal differentiation of oxygen-glucose deprivation/reoxygenation (OGD/R)stimulated NSCs. A further mechanism study revealed that the pro-neurogenesis effects of USC-Exos may be associated with the repression of HDAC6 expression via translocation of exosomal mi-croRNA-26a (miR-26a).
| MATERIAL S AND ME THODS

| Isolation and identification of USCs
Urine-derived stem cells were isolated from the urine samples of healthy adult donors ranging in age from 24 to 28 years, according to the methods described in our previous studies. 16, 37 Written informed consent was obtained from all of the volunteers.
The study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the Ethics Committee 
| Isolation and identification of USC-Exos
Exosomes were isolated from the USC supernatant by differential centrifugation/ultracentrifugation protocols. Briefly, the obtained medium was centrifuged at 300 g for 15 minutes and 2000 g for 30 minutes to remove dead cells and cellular debris. After centrifugation at 10 000 g for 1 hour, the supernatant was further ultracentrifuged at 100 000 g for 2 hours. After the removal of supernatant, the pellet was resuspended in phosphate buffer saline (PBS), followed by another ultracentrifugation at 100 000 g for 2 hours. Finally, pelleted exosomes were resuspended in PBS. Exosome morphologies were detected using transmission electron microscopy (TEM).
Briefly, fresh exosome samples were loaded onto a continuous carbon grid, and then fixed in 3% (w/v) glutaraldehyde and stained with 2% uranyl acetate. The samples were then examined with a Hitachi H-7650 transmission electron microscope (Hitachi). The size and concentration of the exosomes were assessed using flow nanoanalyser instruments according to the manufacturer's instructions. 38, 39 Exosomal markers CD9 (1:1000; Abcam), TSG101 (1:1000; Abcam), Alix (1:1000; Abcam) and negative marker Golgi membrane bound protein (GM130；1:500; Abcam) were detected using Western blot analysis.
| NSC culture
Subventricular zone NSCs were dissociated from Sprague-Dawley (SD) rats and cultured as previously described. 40 The proliferation medium of the NSCs was composed of Dulbecco's modified Eagle medium (DMEM)/F12 media (Gibco) supplemented with 2% (v/v) B27 (Gibco), 20 ng/mL epidermal growth factor (EGF; Perprotech), 20 ng/mL basic fibroblast growth factor (bFGF; Perprotech), 1% penicillin-streptomycin (Gibco) and 2 μg/mL heparin (Sigma). Passages 2-4 were used for the following experiments.
| Application of oxygen-glucose deprivation/ reoxygenation (OGD/R)
To mimic ischaemic-like conditions in vitro, the culture medium of the NSCs was replaced with glucose-free DMEM containing the same supplements as those in the proliferation medium. The NSCs were then transferred to anaerobic conditions (5% CO 2 and 95% N 2 ) for 8 hours. OGD was then ended by changing the medium to glucose and returning the NSCs to normoxia cultured with either the absence (vehicle) or presence of USC-Exos (1 × 10 9 particles/ mL) for 24 hours. Control NSCs were cultured under normal conditions without any treatment. Cells were then harvested for further analysis.
| Assessment of NSC proliferation and neuron differentiation after OGD/R
The 5-ethynyl-2′-deoxyuridine (EdU, 10 µmol/L, Invitrogen) was added to the culture medium following OGD/R. After an additional 24 hours, the cells were stained with Nestin antibody (1:100; Abcam) and EdU click reaction (Invitrogen). Immunoreactive cells were visualized using fluorescence microscopy (Leica). Differentiation of NSCs was induced by withdrawal of EGF and bFGF following OGD/R. At day 7, the differentiation was evaluated with Tuj1 (1:100; Abcam) staining. Each experiment was repeated at least three times. 
| Cell transfection
| Cerebral ischaemia model and USC-Exos injection
All of the animal study protocols were approved by the Animal 
| Uptake of USC-exos in vitro
To determine whether USC-Exos administered intravenously could migrate into the brain, USC-Exos were stained with DiR fluorescent dye (Thermo Fisher), per the manufacturer's instructions. Four hours post-MCAO, the rats were administered a single dose of DiR-labelled exosomes (1 × 10 11 particles in 500 μL PBS). Six hours later, the DiRrelated fluorescence signals were detected using the IVIS Spectrum imaging system (PerkinElmer).
In vitro, USC-Exos were labelled with Dil fluorochrome (Thermo Fisher) according to the manufacturer's instructions and incubated with NSCs for 4 hours. The signals were analysed using a fluorescence microscope (Leica).
| Infarct volume assessment
Brain infarct volume was measured by magnetic resonance imaging (MRI) or cresyl violet staining. For brain MRI study, a 3-Tesla magnetic resonance imaging (MRI) scanner (Siemens) was used to assess the infarct volume at 2 and 28 days post-MCAO. The hyperintense areas in the T2-weighted images over the central 8 images (1.5-mm thick) were used to calculate the infarct volume. The infarct volume of the brain was quantified using ImageJ software (NIH). For cresyl violet staining, infarct volume of was calculated by adding up the infarct areas (contralateral area minus ipsilateral side non-infarct area) of six consecutive slices using ImageJ software (NIH).
| Behaviour test
The modified neurological severity score (mNSS) and the foot-fault test were performed pre-MCAO and 1, 3, 7, 14, 21 and 28 days post-MCAO, as described previously. 41 
| Brain tissue preparation and immunofluorescence
EdU was injected (50 mg/kg) 24 hours before MCAO. On the day 14 after MCAO, the rats were anaesthetized and fixed by transcardiac perfusion with 4% paraformaldehyde. Brains were removed, fixed in 4% formaldehyde overnight at 4°C and immersed in 30% sucrose for 72 hours for cryoprotection. After being embedded and frozen in an optimal cutting-temperature compound, the brains were sliced into 20-μm-thick coronal sections. The brain sections were then stained with specific markers to Nestin (1:100, Abcam), Sox2 
| Western blot analysis
Western blot analysis was performed according to routine protocols.
Primary antibodies used were β-actin (1:1000; Abcam) and HDAC6 (1:1000; Cell Signaling Technology). The intensity of each band was analysed using ImageJ software.
| Quantitative reverse-transcription PCR (qRT-PCR)
The miR-26a expression was detected with a mirVana qRT-PCR miRNA Detection kit (Thermo Fisher Scientific) that included the miR-26a-specific RT primer and quantitative primers, reverse transcriptase and reaction mix. The relative expression of miRNAs was evaluated using the 2 −ΔΔCt method and normalized to U6. Reactions were performed in triplicate, and independent experiments were repeated three times.
| Statistical analysis
Each experiment was repeated at least three times, and the data were presented as mean ± SEM. Statistical analysis was performed using F I G U R E 4 USC-Exos promote SVZ NSC differentiation in rats after ischaemic stroke. A, Representative immunofluorescent staining images and quantitative analysis of EdU (green) and DCX (red) double-positive cells in the subventricular zone (SVZ) of rat brains at 14 d post-ischaemic stroke. B, Representative immunofluorescent staining images and quantitative analysis of EdU (green) and DCX (red) doublepositive cells in the ischaemic brain boundary zone of rat brains at 14 d post-ischaemic stroke. C, Representative immunofluorescent staining images and quantitative analysis of EdU (green) and NeuN (red) double-positive cells in the ischaemic brain boundary zone of rat brains at 14 d post-ischaemic stroke. Scale bar = 100 μm. n = 6/group. * P < .05, ** P < .01; ns = not significant GraphPad Prism 7.0 software. Student's t test and the one-way analysis of variance (ANOVA) with Bonferroni post hoc Tukey test were respectively applied for comparisons between two groups and three groups or more. Statistical significance was considered to be P < .05. 
| RE SULTS
| Characterization of USCs and USC-Exos
Urine-derived stem cells in primary culture presented a fibroblastlike morphology ( Figure 1A) . Cell surface markers were assessed using cytometric analysis. As shown in Figure 1B , USCs were positive for CD29, CD90 and CD73, and negative for CD45, CD34 and HLA-DR. Exosomes were isolated from USC culture supernatant and characterized using TEM, a flow nanoanalyser (NanoFCM) and
Western blot analysis. The results of TEM showed that USC-Exos were spherical vesicles with diameters ranging from approximately 30-100 nm ( Figure 1C ). Flow nanoanalyser analysis revealed that the average diameter was 74.2 ± 16 nm ( Figure 1D) , and the concentration of the USC-Exos was approximately 2 × 10 11 particles/mL.
Western blot analysis revealed that USC-Exos expressed exosomal markers, such as CD9, TSG101 and Alix, whereas the negative marker GM130 was not detected ( Figure 1E ). These data suggested that we had successfully isolated USC-Exos.
| USC-Exos reduce infarct volume and promote functional recovery in rats after ischaemic stroke
To determine whether the intravenous infusion of USC-Exos could migrate into the brain, USC-Exos were labelled with DiR fluorescent dye and administered to rats at 4 hours after MCAO. DiR-labelled USC-Exos-treated rats exhibited visibly high levels of fluorescence intensity in the brain compared to vehicle-treated rats, confirming that USC-Exos could cross the blood-brain barrier and migrate into the brain ( Figure S1A ). We then further investigated the therapeutic effects of USC-Exos in rats after ischaemic stroke. Brain infarct size was monitored using MRI at day 2 and day 28 post-MCAO (Figure 2A ). There was no difference in the original infarct volume measured in the two groups at day 2 post-stroke. However, the infarct volume had significantly decreased in the USC-Exos group compared with the vehicle group at day 28 post-stroke. We also performed cresyl violet staining 28 days after MCAO, which in consistent with MRI result, showed that USC-Exos injection significantly attenuated brain infarct 28 days after MCAO ( Figure 2B ). Measurements from behavioural tests were then used to examine whether USC-Exos treatment led to long-term improvement in behavioural function. As expected, USC-Exos treatment significantly increased functional improvement in both the mNSS ( Figure 2C ) and the foot-fault test ( Figure 2D 
| USC-Exos promote neurogenesis in rats after ischaemic stroke
We then examined whether USC-Exos could enhance neurogenesis after ischaemic stroke in rats. The subventricular zone (SVZ) lining the lateral ventricle (LV) is a major area in which adult NSCs reside, thus making it a potential therapeutic target that may allow neurogenesis. To evaluate the effects of USC-Exos on the proliferation of SVZ NSCs, we quantified EdU + /Nestin + or EdU + /Sox2 + cells at 14 days post-MCAO. As shown in Figure 3A Figure 4B ). These results suggest that USC-Exos promote neurogenesis in rats after stroke, which contributes to improving functional outcome.
| USC-Exos promote proliferation and neuronal differentiation of NSCs subjected to OGD/R
The characteristics of NSCs were identified prior to the following experiments. NSCs cultured in vitro formed spherical free-floating neurospheres ( Figure S2A ). Immunocytochemistry staining revealed that most of the cells in the neurospheres were Nestin/Sox2-positive cells ( Figure S2B ). These characteristics indicate that the cultured neurospheres have phenotypes of NSCs. We then determined whether USC-Exos could be internalized by NSCs. USC-Exos were labelled with Dil fluorescent dye and added to NSC culture media.
After 4 hours of incubation, Dil-labelled USC-Exos were efficiently internalized by NSCs ( Figure S2C ).
The effects of USC-Exos on the proliferation and neuronal differentiation of NSCs after OGD/R were investigated using immunofluorescence. As shown in Figure 5A 
| USC-Exos increase proliferation and neuronal differentiation of OGD/R-stimulated NSCs by inhibiting HDAC6 expression
We then investigated the relationship between HDAC6 expression and the effects of USC-Exos-induced pro-neurogenesis activity in ischaemic stroke. The protein expression of HDAC6 was evaluated in ischaemic rat brains 14 days post-MCAO. As shown in Figure 5A , the expression of HDAC6 was significantly higher in the vehicle group than in the sham group. The expression level of HDAC6 in the USCs-Exo group was significantly lower than that of the vehicle group.
We then confirmed the expression of HDAC6 in NSCs subjected to OGD/R ( Figure 6B ). As expected, the expression of HDAC6 increased after OGD/R. Incubating with USCs-Exo significantly downregulated the expression of HDAC6 in NSCs subjected to OGD/R.
In order to further determine whether HDAC6 was involved in the process of USC-Exos-mediated pro-neurogenesis, an overexpression HDAC6 gene plasmid was transfected into NSCs subjected to OGD/R, and then, NSCs were stimulated with or without USC-Exos for 24 hours. Western blot analysis confirmed the up-regulation efficiency of HDAC6 in NSCs transfected with the HDAC6 overexpression plasmid in the absence of USC-Exos treatment ( Figure 6C ).
NSCs overexpressing HDAC6 were then subjected to functional assays to measure cell proliferation and neuronal differentiation.
Strikingly, HDAC6 overexpression abated the promotion of proliferation and neuronal differentiation in response to treatment with USC-Exos in NSCs subjected to OGD/R (Figure 6D,E) . These data indicate that USC-Exos-induced proliferation and neuronal differentiation in NSCs after OGD/R may be partially attributed to HDAC6 inhibition.
| miR-26a shuttled by USC-Exo increase proliferation and neuronal differentiation of OGD/Rstimulated NSCs by targeting HDAC6
Exosomes mediate cell-to-cell communication by transferring their contents, especially miRNAs. We therefore have been suggested that USC-Exos may affect the expression of HDAC6 by delivering exosomal miRNAs. We detected several miRNAs, including miR-433, 42 miR-22, 43,44 miR-26a, 45 miR-221, 46 miR-548 47 and miR-206, 48 which had been reported to be HDAC6 regulators previously. We found that all of these miRNAs were contained in USC-Exos. In particular, we discovered a higher expression level of miR-26a in USC-Exos ( Figure 7A ). Furthermore, the expression of miR-26a in NSCs after incubation with USC-Exos was determined by qRT-PCR and markedly higher miR-26a expression was detected in USC-Exos-treated group compared with vehicletreated group, suggesting that miR-26a may be transferred into NSCs through USC-Exos ( Figure 7B ). To verify the role of miR-26a in the USC-Exos-mediated promotion of NSC proliferation and neuronal differentiation, USCs were transfected with miR-26a inhibitor or IC, and miR-26a expression was analysed in exosomes isolated from these USC strains (inhibitor-Exos or IC-Exos). A significant decrease in miR-26a expression was detected in inhibitor-Exos compared with IC-Exos ( Figure 7C ). Next, inhibitor-Exos or IC-Exos were incubated with NSCs to investigate the effects of exosomal-transferred miR-26a on HDAC6 expression in NSCs after OGD/R. As illustrated in Figure 7D 
| D ISCUSS I ON
In this study, we found that USC-Exos could significantly attenuated infarct volume and alleviate neurological deficits in post-ischaemic stroke rats. Furthermore, USC-Exos significantly increased the num- Endogenous neurogenesis is known to contribute to repair and recovery in ischaemic stroke. However, this stroke-induced neurogenesis needs to be further increased to attain more neural repair for functional recovery. 7, 20 Exosome-based cell-free therapy, which overcomes the cell-associated limitations in stem cell therapy, could be used as an alternative approach to stem cell infusion methods in the treatment of stroke. 49 USC-Exos are receiving much more attention for tissue repair. In the present study, we F I G U R E 6 USC-Exos increase proliferation and neuronal differentiation of OGD/R-stimulated NSCs by inhibiting HDAC6 expression. A, Protein levels of HDAC6 were measured using Western blot analysis and then quantified with a grey value assay in the peri-infarct brains at 14 d after stroke in each group. n = 3/group. B, Protein levels of HDAC6 were measured using Western blot analysis and then quantified with a grey value assay of NSCs subjected to OGD/R in each group. NSCs subjected to OGD/R were transfected with control vector plasmid or HDAC6 overexpression plasmid, and then, the downstream experiments were performed. C, The efficiency of HDAC6 overexpression plasmid was tested by measuring HDAC6 protein expression using Western blot analysis. D, Immunofluorescence and quantification of EdU (green) and Nestin (red) double-positive cells in different treatment groups. E, Immunofluorescence and quantification of Tuj1 (green)positive cells in different treatment groups. Scale bar = 100 μm. *P < .05, **P < .01 focused on the promotional effects of USC-Exos on neurogenesis after stroke. NSC proliferation is the basic event for neurogenesis.
In the current study, EdU labelling indicated that USC-Exos sig- Increasing evidence has demonstrated that HDAC6 represents a promising target in the development of therapeutic strategies targeting neurogenesis for neurological diseases such as stroke. 30, 51 In this study, we explored the role of HDAC6 in USC-Exos-mediated neurogenesis. Our study found that the expression of HDAC6 significantly increased both in vitro and in vivo ischaemic stroke models. USC-Exos could reduce the expression of HDAC6 induced by stroke models. Furthermore, overexpression of HDAC6 alleviated the pro-neurogenesis effects induced by USC-Exos in NSCs subjected to OGD/R. Therefore, HDAC6 inhibition may be the underlying mechanism by which USC-Exos-induced neurogenesis in ischaemic stroke.
miRNAs are a group of 20-24 nt small non-coding RNAs which can regulate target gene expression by inducing mRNA degradation or translational inhibition. miRNAs have been confirmed to be selectively packaged into exosomes, and exosomes can transfer these miRNAs to target cells or tissues to regulate gene expression. 52, 53 MiR-26a was found to target HDAC6 in myogenic differentiation of embryonic stem cells. 45 More importantly, studies have demonstrated that miRNA-26a positively influenced stroke outcome. 54, 55 Here, we detected high level of miR-26a in USC-Exos.
After treated with USC-Exos for 24 hours, we found that the expression of miR-26a was significantly increased in NSCs subjected to OGD/R, indicating that miR-26a can be transferred into NSCs through USC-Exos. Furthermore, results of our study revealed that the effects of HDAC6 inhibition and pro-neurogenesis induced by USC-Exos were notably reversed by miR-26a inhibitor-Exos in vitro.
These findings suggest that miR-26a may be one of the critical mediators in USC-Exos-mediated pro-neurogenesis via targeting HDAC6. However, our present results could not exclude the possibility that other substances in USC-Exos, such as other miRNAs, proteins or lipids, may also play roles in USCs-Exo-induced neurogenesis by regulating HDAC6. Further investigation is also required to verify the role of miR-26a/HDAC6 axis in USC-Exos-mediated neurogenesis in vivo.
In summary, our research for the first time confirms that USC-Exos exalt both proliferation and neuronal differentiation of cultured NSCs subjected to OGD/R, and promote neurogenesis in rats after stroke, potentially through miR-26a/HDAC6 axis. Our finding of USC-Exos promoting neurogenesis may open a new avenue for stroke treatment.
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F I G U R E 7 miR-26a shuttled by USC-Exo increase proliferation and neuronal differentiation of OGD/R-stimulated NSCs by targeting HDAC6. A, RT-qPCR analysis showed that miRNAs reported to be HDAC6 regulators, including miR-433, miR-221, miR-26a, miR-22, miR-548 and miR-206, are contained in USC-Exos. B, Exosomes were isolated from USCs transfected with 100 nmol/L inhibitor (inhibitor-Exos) or inhibitor control (IC-Exos) as indicated. MiR-26a expression was analysed in IC-Exos or inhibitor-Exos by RT-qPCR. C, Expression levels of miR-26a in different treatment groups. D, Expression of HDAC6 in different treatment groups. E, Immunofluorescence and quantification of EdU (green) and Nestin (red) double-positive cells in different treatment groups. F, Immunofluorescence and quantification of Tuj1 (green)-positive cells in different treatment groups. Scale bar = 100 μm. P < .05, **P < .01
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